A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause

OBJECTIVE: Menopausal vasomotor symptoms (VMS) may result from altered thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing neurons. This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraser, Graeme L., Lederman, Samuel, Waldbaum, Arthur, Kroll, Robin, Santoro, Nanette, Lee, Misun, Skillern, Laurence, Ramael, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott-Raven Publishers 2020
Materias:
Original Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147405/
https://www.ncbi.nlm.nih.gov/pubmed/32102086
http://dx.doi.org/10.1097/GME.0000000000001510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147405/
https://www.ncbi.nlm.nih.gov/pubmed/32102086
http://dx.doi.org/10.1097/GME.0000000000001510

Ejemplares similares